Testosterone (T) is the principal male sex hormone. As men age, T levels typically fall. Symptoms of low T include decreased libido, vasomotor instability, and decreased bone mineral density. Other symptoms may include depression, fatigue, erectile dysfunction, and reduced muscle strength/mass. Epidemiology studies show that low levels of T are associated with more atherosclerosis, coronary artery disease, and cardiovascular events. However, treating hypogonadism in the aging male has resulted in discrepant results in regard to its effect on cardiovascular events. Emerging studies suggest that T may have a future role in treating heart failure, angina, and myocardial ischemia. A large, prospective, long-term study of T replacement, with a primary endpoint of a composite of adverse cardiovascular events The purpose of this review is to discuss the basic endocrinology of T, hypogonadism in the young and the elderly, the association between low T and cardiovascular (CV) risk, and approaches to treating hypogonadism. This review will also discuss controversies regarding the administration of exogenous T to patients with hypogonadism, the use of T in heart failure, its effect on thromboembolism and ischemia/reperfusion injury, and recent changes in labeling for T replacement therapy (TRT).
T estosterone (T) is the principal male sex hormone, secreted primarily by the testes and, to a lesser extent, by adrenal glands. This hormone's androgenic effects are responsible for the maturation of male sexual organs, as well as for secondary sexual characteristics (growth of beard, axillary, and pubic hair, and deepening of voice). T is needed for the development of normal sperm production and contributes to sex drive. It also has anabolic effects, including promotion of muscle mass, strength, bone density, and maturation. T is also produced in small quantities in the ovaries; women have a much lower level of T than men. T levels decrease with age, and this decrease has been associated with an increase in atherosclerosis and cardiovascular risk. One might conclude that replacing T would reduce the risk; however, clinical studies on this concept have shown discrepant results.
The purpose of this review is to discuss the basic endocrinology of T, hypogonadism in the young and the elderly, the association between low T and cardiovascular (CV) risk, and approaches to treating hypogonadism. This review will also discuss controversies regarding the administration of exogenous T to patients with hypogonadism, the use of T in heart failure, its effect on thromboembolism and ischemia/reperfusion injury, and recent changes in labeling for T replacement therapy (TRT).
THE HYPOTHALAMUS-PITUITARY-TESTES AXIS
The controller of the gonadal axis is gonadotropinreleasing hormone (GnRH), which is released from the hypothalamus (Figure 1 LABORATORY DIAGNOSIS. The laboratory diagnosis of hypogonadism requires documentation of low serum T levels on at least 2 morning samples drawn before 10 AM. Free T is considered the better test because total T can be elevated in situations of elevated SHBG (aging), or the total can be low when SHBG levels are reduced (diabetes, obesity). An analysis for FSH and LH should be done to distinguish between primary versus centrally mediated hypogonadism. If a pituitary tumor is of concern, then a prolactin level should be obtained. Although most agree that a total T of <300 ng/dl is considered low, it is best to use the normal ranges of the specific laboratory making the measurement. the presence of symptoms (3) . Specific signs and symptoms of male hypogonadism include vasomotor instability (hot flashes), decreased libido (4), and decreased bone mineral density (BMD) (5) . There are clear data that T treatment will relieve hot flashes, improve libido, and increase bone mass (6) . Similarly, there are consistent data from both the literature (7) and from studies of frail older men (8) that T therapy will increase lean body mass. In the recently published TOM (Testosterone in Older Men With Mobility Limitations) study, this increase in muscle mass translated to improved strength (8) .
The data on erectile function generally show an improvement with T therapy, but the benefit is more pronounced in men with lower serum levels of T at baseline and in younger, healthier men, with little vascular disease.
Numerous studies have shown an age-related decline in both total and free T, even in the presence of an age-related increase in SHBG (9) . The defect is thought to occur mainly at the level of the hypothalamus and pituitary gland, and is characterized as a blunted response to GnRH stimulation.
Approximately 25% of men >65 years of age will have low total T levels, and at least 50% will have low levels when using free T as the diagnostic criterion.
Similarly, there are numerous chronic illnesses associated with reductions in serum T that can be attributed to inflammation with elevated cytokines.
The frequency of male hypogonadism varies greatly on the basis of the population studied. It is no surprise that sicker men will have age-related declines. In population-based studies, the prevalence of hypogonadism is 54% in a hospitalized, ill population (10,11) and 50% among type 2 diabetes mellitus patients (12) . As with age-related decline, it is unclear whether chronic illness-related decline should be treated with T therapy.
The less specific findings of reduced T levels include depression, fatigue, erectile dysfunction (ED), and reduced muscle mass. These nonspecific symptoms can be difficult to define in clinical trials.
There is some improvement in the overall sense of well-being with T therapy (13) , but the data are relatively few when it comes to randomized, placebocontrolled studies. One reason for this is the variability in age, symptoms, and serum T levels in the enrolled populations. It must be emphasized that the Food and Drug Administration (FDA) has never required that any new T product prove efficacy.
The FDA only requires adequate pharmacokinetics.
LOW T LEVELS AND CARDIOVASCULAR RISK
As stated, serum T level declines gradually with age in most men (14). Epidemiological and observational studies have shown that low T is associated with increased CV disease risk (15) (16) (17) . A meta-analysis of 70 studies indicated that patients with CV disease demonstrated significantly lower T and higher 17-b estradiol levels, which remained significant markers after adjusting for age and body mass index (16) . In longitudinal studies, the baseline T level was lower in those with cardiovascular mortality. Testosterone affects the brain with stimulation of libido and aggression; muscle strength and mass; bone growth and density; sex organ growth, along with spermatogenesis and erectile function; kidney production of erythropoietin; and skin effects, including hair growth. T ¼ testosterone.
Kloner et al. For congenital causes, boys should start therapy about the time of normal puberty (i.e., <14 years of age) and continue for life. The type and route of administration for T is primarily of personal preference. Each differs by its pharmacokinetic profile or frequency of administration (27) .
Caution should be used in the administration of T therapy to men who may be interested in fertility.
One of the clear side effects of exogenous T is suppression of the endogenous gonadal axis, resulting in suppressed spermatogenesis.
THE USE OF TRT IN MATURE AND OLDER MEN WITH HYPOGONADISM
Age-related hypogonadism is common (28) and becoming more recognized, likely due, in part, to directto-consumer advertising. Various society guidelines emphasize the need to not only measure serum sex hormone levels (2 morning samples, a few days apart), but also to correlate them to symptoms and signs.
Unfortunately, many of the symptoms are nonspecific, thus making it difficult to conclude whether the presenting clinical scenario is due to aging or hypogonadism.
The goal of TRT is to restore T levels to normal physiological ranges and to reverse the physiological effects of hypogonadism. Kloner et al.
Testosterone and Cardiovascular Disease
Fatigue is a common complaint of hypogonadal men seeking treatment (49, 50) . Fatigue and vigor improved in a placebo-controlled trial of TRT using a nonvalidated outcome instrument to assess fatigue (50) .
TRT has been extensively studied for changes in muscle mass and body composition. The majority of these studies of body composition in hypogonadal men showed improvements by TRT in lean body mass with decreased fat mass (51) (52) (53) (54) .
In a recent study (55) , those men treated with TRT and resistance training had a decrease in fat mass, and increases in lean mass and upper body strength compared with men taking placebo. In the TOM study of frail elderly men with mobility limitations, stair-climbing power, leg-press strength, and chest-press strength were significantly improved in men receiving TRT versus placebo (56). Hypogonadism is common in men with metabolic syndrome and type 2 diabetes mellitus, and is also associated with poor glycemic control, insulin resistance, visceral adiposity, and dyslipidemia (64, 65) .
Diabetes mellitus is associated with hypogonadism in as many as 50% of patients with type 2 diabetes (50).
In T was associated with an event rate that was reduced by more than one-half, and it was not until statistical manipulations were performed that the opposite conclusion was reached. Other criticisms of this paper included the concern that men with MI or stroke who were given T after these events were excluded from analysis. However, had they been included, the rate of events in the no-treatment group would have been substantially increased. Starting on T did not ensure that it would be continued: 17.6% of patients in the T group had only 1 prescription filled, and only 60% of patients had follow-up T levels determined after therapy had started. In those patients that did have post-treatment levels determined, the average treat- Other reasons for discrepancies in published reports might relate to the type of T that is measured.
Some investigators think that free T or bioavailable T levels should be measured, as well as total T. The types of statistical analyses in these studies were variable, and as pointed out, 1 study showed raw numbers that favored T therapy, whereas extensive statistical recalculation showed a detrimental effect of this therapy (72, 73) . 
PROPOSED PROSPECTIVE STUDY
A proposed study to definitively answer the question of whether TRT has adverse effects on CV safety is needed. It should be a large, prospective, randomized, placebo-controlled, double-blinded, long-term study (at least 1 year and preferably longer).
Entrance criteria should require the men to have symptomatic hypogonadism, verified by low T (total, free, bioavailable) levels obtained on at least 2 separate morning blood draws. At least 2 T-type preparations should be studied (intramuscular injections and
Kloner et al. 
POTENTIAL FUTURE CARDIOVASCULAR USES OF T
Besides safety issues of T, there has also been interest in its use as a potential therapy for certain CV disorders. These include using T for heart failure, angina, and ischemia/reperfusion injury.
T THERAPY IN HEART FAILURE WITH REDUCED EJECTION FRACTION
T deficiency (total and estimated free T) has been demonstrated in 26% to 37% of male patients with chronic heart failure (HF) with reduced ejection fraction (95) (96) (97) . Reduced T levels are associated with increased systemic vascular resistance, lower heart rate variability, and depleted baroreflex sensitivity (98, 99) . In addition to the chronic anabolic state seen in HF, the reasons for reduced T levels are likely multifactorial, with hepatic congestion leading to an increase in SHBG levels, with a subsequent decrease in free T levels (100,101). Low T is frequently associ- 
CONCLUSIONS
Testosterone has a role in therapy of true symptomatic hypogonadism in both young and older men ( Table 1) . There appear to be no major concerns for using T in young, healthy men with specific indications for TRT. Testosterone has specific effects on the CV system ( Table 2 ). 
